Tislelizumab-Jsgr (1 brand name, 2 dosage forms, 2 routes)
Available dosage forms: INJECTABLE, INJECTION.
Routes of administration: INTRAVENOUS, SOLUTION.
Brand Names
- TEVIMBRA
Contraindications
None.
Adverse Reactions
The following clinically significant adverse reactions are discussed in more detail in other sections of the label: Severe and fatal immune-mediated adverse reactions [see Warnings and Precautions (5.1)] Infusion-related reactions [see Warnings and Precautions (5.2)]
Mechanism of Action
Binding of the PD-1 ligands PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Tislelizumab-jsgr binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. Tislelizumab-jsgr decreased tumor growth in xenograft models and a human PD-1 transgenic mouse model.